Immunic Inc announced that four abstracts on its multiple sclerosis drug candidate, vidofludimus calcium, will be presented at the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto from October 21-23, 2026. The presentations highlight clinical and mechanistic data supporting the drug's unique profile, including long-term disability outcomes, neuronal survival effects, and reductions in Epstein-Barr virus-specific immune markers. These findings reinforce vidofludimus calcium's potential as a differentiated oral therapy for progressive MS, with all abstracts to be published in the Multiple Sclerosis Journal's online supplement.
Immunic's vidofludimus calcium is the story subject, with Pluang health-sector data providing market context. Of 100 health-sector US stocks on Pluang, 56 rose and 43 fell today. Notable movers include TXG at USD 75.62 with a 6.24% drop and 54% buy activity, RXRX at USD 4.35 down 6.05% with 21% buy activity, and TWST at USD 157.86 down 5.46% with 46% buy activity. Data is as of Oct 07, 2026 21:21 WIB.
BNP Paribas lowered Hormel Foods' price target from $26 to $23, indicating a potential 16.2% upside from its current price of around $19.80. Despite a 50.5% decline in its share price over five years, Hormel Foods remains attractive for dividend inve...
Barclays initiated coverage of Becton, Dickinson and Company (BDX) with an "Underweight" rating, indicating a cautious outlook for the medical technology stock. BDX is partnering with the U.S. government to boost domestic manufacturing and strengthen...
Morgan Stanley increased its price target for Eli Lilly to $1,430 from $1,419, maintaining an Overweight rating. This new target implies a potential upside of about 20.8% from the current share price of around $1,184. The adjustment reflects updated ...
Arthur J. Gallagher expects about 6% organic growth in Q3, driven by strong client retention and new business despite easing property insurance pricing. Cantor Fitzgerald lowered its price target to $280, below the $288 average from 19 analysts who m...
Needham raised Zscaler's price target to $255, citing strong demand for AI-related cybersecurity solutions. Zscaler aims to exceed $8 billion in annual recurring revenue by fiscal 2031, driven by increasing needs to protect against AI-powered cyberat...
